Ani Pharmaceuticals Inc

This advisory (non-binding) 'say-on-pay' proposal asks stockholders to approve the compensation paid to the Company’s named executive officers as described in the proxy statement. Management seeks this advisory approval to validate its pay-for-performance philosophy, which ties significant compensation to both short-term corporate objectives and longer-term performance-based equity (PSUs and restricted stock), and to demonstrate alignment between executive incentives and shareholder value creation. Relevant context includes the Company’s strong 2025 financial performance (record net revenues and increased adjusted non-GAAP EBITDA), resulting in above-target payouts under the annual incentive plan and materially larger equity grants tied to multi-year EBITDA growth and relative TSR metrics. The Board highlights governance features intended to limit dilution and risk, including clawback provisions, double-trigger change-in-control protections, minimum vesting periods, limits on repricing, and director grant caps. Management frames the ask as routine and emphasizes prior stockholder support (89.6% approval in the prior year) and ongoing engagement with investors. Because the vote is advisory, its outcome will not mandate changes, but a negative result would prompt the Board and Compensation Committee to consider shareholder feedback and possibly adjust program design. The Board recommends a 'FOR' vote on the basis that current compensation structures have supported strong operational execution and align executive pay with long-term shareholder returns while incorporating risk-mitigating governance practices. The proposal therefore functions as a governance touchpoint that enables shareholders to express their view on pay without altering contractual obligations directly.

This proposal asks shareholders to indicate, on a non-binding basis, how often the company should hold advisory 'say-on-pay' votes — once every 1, 2, or 3 years (or abstain). Management recommends an annual (1-year) frequency, arguing that annual votes provide the most timely and direct mechanism for shareholders to express views on executive pay and enable the Board and Compensation Committee to respond promptly to investor feedback. The proposal arises from Dodd-Frank requirements to solicit a frequency preference periodically and comes against a backdrop of active shareholder engagement and recent, sizable equity awards tied to both financial and TSR performance metrics. An annual frequency increases the cadence of governance feedback but does not change substantive compensation arrangements because all votes are advisory. If no single option receives a majority, the Board has stated it will consider the plurality result in making future decisions. The Company’s rationale balances transparency and responsiveness with administrative burden; management contends that the benefits of frequent stockholder input outweigh the incremental costs of annual voting. For investors evaluating the proposal, considerations include how quickly the company’s compensation program evolves, the degree of shareholder concern about pay practices, and whether more frequent votes produce meaningful changes in compensation policy. The Board’s endorsement of the 1-year option signals its willingness to receive frequent feedback and maintain accountability on pay matters, which may be viewed positively by governance-focused investors.

This proposal asks shareholders to approve an amendment to the Company’s 2022 Stock Incentive Plan to add 962,000 shares to the plan reserve, increasing the total authorized share pool to 8,222,000 shares upon approval. Management’s stated rationale is workforce retention and competitiveness: the Company has used equity as a central element of compensation, including significant restricted stock and performance stock unit grants tied to multi-year EBITDA growth and relative TSR, and believes the current share reserve is insufficient to support future grants for executives, employees and non-employee directors. The proposal includes governance-minded guardrails — e.g., no discounted options, anti-repricing without shareholder approval, minimum vesting requirements (with limited exceptions), director grant caps, no evergreen provision, and limitations on dividend equivalents — which management highlights to limit dilution and protect shareholder interests. The proxy discloses recent burn-rate and overhang metrics, historical grant levels, and usage (2025 burn rate ~4.15% and overhang around 9–10%), allowing investors to evaluate dilution versus retention needs. Approving the increase would permit continued use of equity-linked incentives that align employee interests with long-term shareholder value, while opponents may focus on incremental dilution and whether alternative cash-based retention tools or more conservative equity usage should be prioritized. The Board recommends approval, arguing the amendment is necessary to sustain the Company’s compensation program and future talent needs while maintaining meaningful plan limits and governance features to mitigate shareholder dilution and preserve alignment. Investors evaluating the proposal should weigh the Company’s growth trajectory, recent equity utilization, and the plan safeguards against the potential dilutive impact of additional authorized shares.